VIJAYA · NSE
Vijaya Diagnostic Centre Limited
₹1,558.9
+3.51% (+₹52.8)
Prev. close
₹1,506.1
Volume
2,78,137
Delivery %
38.6%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Vijaya Diagnostic Centre Limited
Vijaya Diagnostic Centre Limited provides diagnostic services for patients in India. The company offers laboratory services, including clinical pathology, microbiology, haematology, serology, histopathology, cytogenetics, biochemistry, and molecular diagnostics; radiology services, such as CT scan, magnetic resonance imaging (MRI) scan, ultrasound, X-ray, cardiology, and gastroenterology; and advance radiology service comprising nuclear medicine, positron emission tomography CT, and MRI-3T services. It also provides health checkups and home sample collection services, as well as test services. Vijaya Diagnostic Centre Limited was founded in 1981 and is based in Hyderabad, India.
Details
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Ms. Sura Suprita Reddy
Headquarters
Hyderabad
Employees
2,507
Website
vijayadiagnostic.comExchange
View on NSE ↗Key stats
Market cap
₹16,056.31 Cr
P/E ratio (TTM)
85.6
Dividend yield
0.13%
EPS (TTM)
₹18.22
Beta (1Y · daily vs NIFTY 50)
0.52
Beta (5Y · monthly vs NIFTY 50)
0.75
Shares float
4.89 Cr
EPS · quarter ended Jun 2026
₹5.15
Financial Performance
01 · Financials
FY22 growth needs FY21 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹462.37 Cr | ₹459.22 Cr | ₹547.81 Cr | ₹681.39 Cr | ₹814.20 Cr | |
| EBITDA | — | ₹216.52 Cr | ₹196.18 Cr | ₹239.67 Cr | ₹290.51 Cr | ₹357.73 Cr |
| — | ₹109.68 Cr | ₹84.63 Cr | ₹118.83 Cr | ₹143.08 Cr | ₹172.98 Cr | |
| Diluted EPS | — | ₹10.69 | ₹8.26 | ₹11.59 | ₹13.92 | ₹16.79 |
Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense, Other income, Diluted EPS have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹541.24 Cr | ₹713.46 Cr | ₹853.41 Cr | ₹982.75 Cr | ₹1,273.62 Cr | ₹1,507.05 Cr | |
| ₹141.05 Cr | ₹182.83 Cr | ₹247.56 Cr | ₹259.18 Cr | ₹319.58 Cr | ₹422.59 Cr | |
| Stockholders' equity | ₹359.01 Cr | ₹468.22 Cr | ₹544.73 Cr | ₹657.19 Cr | ₹795.71 Cr | ₹957.15 Cr |
Fixed assets, CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹158.00 Cr | ₹164.61 Cr | ₹183.30 Cr | ₹224.47 Cr | ₹270.59 Cr | |
| Investing cash flow | — | ₹-123.06 Cr | ₹-109.57 Cr | ₹-142.31 Cr | ₹-181.87 Cr | ₹-174.22 Cr |
| — | ₹-30.57 Cr | ₹-41.91 Cr | ₹-44.55 Cr | ₹-52.05 Cr | ₹-69.49 Cr | |
| Capital expenditure | — | ₹-122.35 Cr | ₹-124.84 Cr | ₹-87.96 Cr | ₹-95.55 Cr | ₹-182.72 Cr |
| End cash position | ₹6.69 Cr | ₹11.05 Cr | ₹24.18 Cr | ₹22.25 Cr | ₹12.80 Cr | ₹39.68 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt repaid, Dividends paid, Capital expenditure have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Mar 22(3Q) | Jun 22 | Sep 22–Mar 23(3Q) | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24–Dec 24(2Q) | Mar 25 | Jun 25 | Sep 25–Dec 25(2Q) | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 54.78% | 55.04% | 55.01% | 54.98% | 54.90% | 54.87% | 54.06% | 53.93% | 53.91% | 53.05% | 52.63% | 52.60% | 52.51% | 52.47% |
| Public | 45.22% | 44.96% | 44.99% | 45.02% | 45.10% | 45.13% | 45.94% | 46.07% | 46.09% | 46.95% | 47.37% | 47.40% | 47.49% | 47.53% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Vijaya Diagnostic Centre Limited | ₹14,814.16 Cr | ₹1,506.1 | 79.1 | 15.48 | 18.1% | 0.44 | +19.5% | +43.5% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Show all 12
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
13 indices
Weight is a free-float market-cap-share estimate from NSE’s live index data, not NSE’s own published (and sometimes capped) index weight. Indices without a live weight feed are listed without one, in alphabetical order after the weighted ones.
Diagnostic Chain Stock Rises 43% in 1 Year: What Drove It
Vijaya Diagnostic Centre Ltd's stock rose 43% in one year, driven by five consecutive quarters of margin expansion and strong financial results. The company reported a 42.7% EBITDA margin and 37.6% profit growth in the June 2026 quarter. A recent Rs 46.20 crore acquisition in Guwahati also contributed to the gains.
Vijaya Diagnostic Centre Ltd. (VIJAYA) Share Price rises 5.05% as stock gains today
Univest · 2 days ago